UNSPSC 51362007: Flurazepam monohydrochloride

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C4JH842IJ, chemically known as 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1), but more generally known as flurazepam monohydrochloride, which bears US NIH Compound Identifier 37368.

European Medicines Agency schedules flurazepam monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07744MIG. Most nations, for tariff purposes, schedule flurazepam monohydrochloride under HS 29339190. Flurazepam monohydrochloride bears US NLM identifiers UMLS ID C0887259 and NCI Concept Code C98134. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.

UNSPSC 51362007 Flurazepam monohydrochloride is a Commodity code that nominally covers a specific benzodiazepine pharmaceutical product, though recent state and local procurement activity under this code does not reflect purchases of flurazepam itself. Instead, the single recent opportunity tagged to this code involves procurement of naloxone and drug deactivation systems — products unrelated to the code's stated scope. This mismatch suggests the code may have been applied incorrectly by the issuing jurisdiction, or that state and local procurement offices are using this code designation inconsistently. The code shows minimal recent activity in state and local markets, and business development activity targeting this specific pharmaceutical commodity should be treated with caution given the apparent disconnect between the code's nominal purpose and actual buying patterns.

Seminole County, Florida posted the only recent opportunity under this code: an IFB (Solicitation Number IFB60459723LAS) released on Jun 30, 2026 for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement was structured as a competitive IFB with a two-year initial term and one-year renewal option, requiring vendors to cover all shipping and delivery costs. The procurement potentially involved FEMA funding, introducing federal compliance requirements. Given the single, mislabeled opportunity and the fundamental scope mismatch between the code definition and actual procurement, this code does not represent a reliable or substantive opportunity area for flurazepam or related pharmaceutical products in state and local markets.